The association between nephrosclerosis and systemic atherosclerosis is not clear. In this study, we investigated the compound screening assay association between CA-IMT and nephrosclerosis in a group of kidney transplant donors. Methods:  Forty seven potential kidney transplant donors were included. CA-IMT was measured by B-Mode ultrasonography. Kidney allograft biopsy samples were obtained during the transplantation operation and chronic glomerular, vascular and tubulointertitial changes were semiquantitatively scored according to the Banff classification. Results:  Mean age was 52 ± 12 years and 55% of the cases were younger than 55 years. Mean CA-IMT was 0.74 ± 0.19 mm and 48% had IMT values > 0.75 mm. Chronicty

index was ≥5 in 55% of the cases. Chronicity index was higher in cases older than 55 years. Age and CA-IMT were significantly BIBW2992 chemical structure correlated with chronic vascular changes and chronicity index. CA-IMT > 0.75 mm had a 46% sensitivity and 90% specificity to predict nephrosclerosis. Positive and negative predictive values were 85% and 57%, respectively. Conclusion:  Aging leads to detrimental changes in every part of the vasculature of the human body. CA-IMT is correlated with the level of nephrosclerosis. Measurement of CA-IMT reflects nephrosclerosis especially

in older patients. “
“Dialysate prescription is evolving as new technology allows greater opportunity to alter dialysate constituents throughout dialysis, providing scope for tailored prescription for an individual patient. The intention of modelling or profiling Mirabegron is to improve the tolerability of dialysis and long-term patient outcomes. This approach can be applied to both electrolytes and water. Despite these advances in technology, benefits of modelling have not been demonstrated consistently. This review examines the use of individual prescription and modelling of dialysate sodium, ultrafiltrate, potassium, calcium, magnesium, bicarbonate and phosphate. With older and

increasingly complex patients, the potential benefits of individual prescription of dialysate have gained more relevance. In most dialysis centres dialysate is prepared, centrally, to provide a predetermined standard composition. Individual dialysate prescription may involve setting concentration of each solute at the start of dialysis and adjustment of the concentration of some solutes throughout the dialytic period, so-called modelling or profiling of the dialysate. The need to improve both intradialytic and interdialytic morbidities and long-term outcomes has driven the use of individualized prescription. The goal of this review is to summarize current evidence for individualizing dialysate composition, with a focus on conventional, thrice weekly dialysis. Considerable effort has been focussed on determining the optimum concentration of dialysate sodium.